$CBDD the 2nd acquisition, CBDD and its majority
$CBDD the 2nd acquisition, CBDD and its majority shareholder Swiss Industry Ventures, AG, are positioned to become a leader in the Swiss CBD market. Switzerland is in a central location, surrounded by 5 EU countries and is the business and banking hub of the Europe. The company looks to expand its customer base quickly in adjoining countries.
CBDD has engaged Executive Industries, Inc. to complete our ongoing financial filings and keep us in compliance with OTC Markets. We have also retained Jonathan D. Leinwand, P.A., a law firm experienced in CBD, cannabis, corporate and securities law. Their expertise in mergers and acquisitions will be an indispensable asset as we move forward with our corporate objectives.
The Revenues from the first two acquisitions will be consolidated and included in our Q2 financial filing due on June 30th.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
PotlatchDeltic Reveals Dividend Tax Treatment for 2024 PotlatchDeltic Corporation (Nasdaq: PCH) is stepping into the spotlight by announcing the tax treatment for its anticipated dividend distributions throughout the year. As a prominent player in the real estate investment sector, this announcement brings clarity to investors regarding how dividends will be categorized...
Continue Reading
Beyond Air's Strategic Moves to Boost Capital Beyond Air, Inc. (NASDAQ: XAIR), a leading medical device and biopharmaceutical company, is making waves in the financial realm. Focused on the innovative use of nitric oxide (NO) to enhance patient care, Beyond Air has announced the immediate exercise of certain outstanding warrants, aiming to generate approximately $3.25...
Continue Reading
Saisei Ventures Welcomes Dr. Sven Kili as Partner Saisei Ventures, a prominent investment firm focused on the advancement of biotechnology and therapeutic innovations, has announced an exciting new chapter in its journey. Dr. Sven Kili, MD, has been appointed as a partner, marking a significant addition to the team's leadership. Dr. Kili, who played an advisory role since...
Continue Reading
Mangoceuticals, Inc. (NASDAQ: MGRX) launched its new oral Tirzepatide tablet, TRIM, back in 2024 at a steep price of $399 per month. Traders noticed this shift towards a convenient alternative to traditional injectables and were already debating the long-term implications on sales and market share. TRIM's Role: A Game Changer for Weight Management? Tirzepatide has made...
Continue Reading
Mama’s Creations to Host Earnings Call for Second Quarter FY2025 Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, is preparing to announce its financial results for the fiscal second quarter, which ended on July 31. The earnings call is scheduled to take place after the market closes on September 10....
Continue Reading
